(Circulation. 2000;101:71.)
© 2000 American Heart Association, Inc.
Basic Science Reports |
ß2-Adrenergic Receptor Overexpression Exacerbates Development of Heart Failure After Aortic Stenosis
From the Baker Medical Research Institute, Melbourne, Australia.
Correspondence to X.-J. Du, Baker Medical Research Institute, St Kilda Road Central, PO Box 6492, Melbourne 8008, Victoria, Australia. E-mail xiaojun.du{at}baker.edu.au
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—ß-Adrenergic signaling is downregulated in the failing heart, and the significance of such change remains unclear.
Methods and Results—To address the role of ß-adrenergic dysfunction in heart failure (HF), aortic stenosis (AS) was induced in wild-type (WT) and transgenic (TG) mice with cardiac targeted overexpression of ß2-adrenergic receptors (ARs), and animals were studied 9 weeks later. The extents of increase in systolic arterial pressure (P<0.01 versus controls), left ventricular (LV) hypertrophy (TG, 94±6 to 175±7 mg; WT, 110±6 to 168±10 mg; both P<0.01), and expression of ANP mRNA were similar between TG and WT mice with AS. TG mice had higher incidences of premature death and critical illness due to heart failure (75% versus 23%), pleural effusion (81% versus 45%), and left atrial thrombosis (81% versus 36%, all P<0.05). A more extensive focal fibrosis was found in the hypertrophied LV of TG mice (P<0.05). These findings indicate a more severe LV dysfunction in TG mice. In sham-operated mice, LV dP/dtmax and heart rate were markedly higher in TG than WT mice (both P<0.01). dP/dtmax was lower in both AS groups than in sham-operated controls, and this tended to be more pronounced in TG than WT mice (-32±5% versus -16±6%, P=0.059), although dP/dtmax remained higher in TG than WT groups (P<0.05).
Conclusions—Elevated cardiac ß-adrenergic activity by ß2-AR overexpression leads to functional deterioration after pressure overload.
Key Words: genetics • receptors, adrenergic, beta • hypertrophy • heart failure • pressure
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Under conditions of heart failure (HF), the ß-adrenergic pathway is markedly attenuated through the downregulation and uncoupling of ß1-adrenergic receptors (ARs).1 This involves receptor phosphorylation by ß-AR kinase (ßARK1, GRK-2) and the subsequent binding of receptors with ß-arrestins.1 2 3 In the failing myocardium, ß1-AR mRNA levels are reduced and the expression of ßARK and ß-arrestins is increased.1 3 4 5 ß2-AR density remains unchanged, but uncoupling of ß2-ARs has been reported.1 2 3 5 Other related changes include reduction in stimulatory GTP-binding protein (Gs),1 2 3 suppressed activity of adenylyl cyclase,1 2 and upregulation of inhibitory G protein (Gi).1 6
The significance of the changes to the ß-adrenergic system in HF, however, is not clear. There are 2 opposing views. One position is that the attenuated ß-adrenergic pathway in the failing heart protects against adrenergic overstimulation and therefore is salutary. Accordingly, the beneficial effects of ß-blockade in the treatment of HF could be due to further prevention of such overstimulation. The other view holds that the changes seen in the ß-adrenergic system are responsible for the loss of adrenergic support of myocardial contractility and therefore contribute to the progression and worsening of HF. This view is consistent with the poor tolerance of NYHA class IV patients to ß-blockers and the decline in cardiac function in HF patients in the early phase of ß-blocker therapy.7 Studies have also shown that the failing human myocardium generates nearly normal tension when stimulated with Ca2+ or cardiac digitalis, but the inotropic responses to activators of ß-AR and adenylyl cyclase are blunted.1 2 All of these findings imply an importance of functional support by the ß-adrenergic system in the failing heart. From this point of view, the possible mechanism of protection afforded by ß-blockade in chronic HF patients could be the partial reversal of the suppressed ß-adrenergic system. Indeed, ß-blockade1 8 9 10 or expression of an inhibitor for ßARK1, ßARKct,11 12 13 has been shown to decrease ßARK expression and increase ß1-AR density and ß-AR sensitivity to catecholamines in the failing myocardium.
Milano et al14 developed a transgenic (TG) strain in which
the human wild-type (WT) ß2-AR gene was
expressed under a mouse 
-myosin heavy chain (-MHC) promoter. This
leads to an overexpression of the transgene with 
200-fold increase
in ß2-AR density in the heart. TG mice show
elevated cAMP levels and enhanced ventricular
contractility and heart rate (HR) in the absence of
agonist stimulation. This agonist-independent activation is explained
by the ability of ß2-AR to spontaneously form
the active conformation. Whereas the inactive conformer is by far the
predominant one, with a nearly 200-fold increase in
ß2-AR density, the number of "active"
receptors would be substantially higher and sufficient to support a
full physiological stimulation.14 15
This TG model provides a unique opportunity to study the role of the
ß-adrenergic system in HF. In this model, the ß-adrenergic system
is constitutively activated and would be expected to provide
continued functional support under conditions of cardiac disorders. The
aim of this study was to test whether enhanced ß-adrenergic activity
and myocardial contractility might attenuate the
development of HF after aortic stenosis.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Mice and Transgene Screening
Parent TG mice (TG4) were generated at the Howard Hughes Medical Institute, Duke University Medical Center.14 Male TG mice were crossed with female F1 mice from the C57BL and SJL strains. The genomic DNA was extracted from tail biopsy, and expression of the transgene in offspring was detected by Southern blot hybridization using a 32P-labeled HincII fragment of the transgene construct.14 Both male and female animals, 3 to 6 months old, were used in this study.
Microsurgery
Mice were anesthetized (with a mixture of 8 mg/100 g
ketamine, 2 mg/100 g xylazine, 0.6 mg/100 g atropine, and the
pain reliever temgesic at 0.1 mg/100 g), intubated, and ventilated.
Under a surgical microscope, a midline incision was made at the upper
sternum. The aorta was dissected between the right innominate and the
left carotid arteries and narrowed to a lumen size of 0.4 mm
according to a method previously described.16 Control mice
underwent similar surgery except for the narrowing of the aorta. The
surgical procedures were approved by a local Animal Experimentation and
Ethics Committee.
Functional Measurement
Cardiac function was assessed by a catheter placed into the
right carotid artery (proximal to the stenotic site) and the
left ventricle (LV). Mice were anesthetized with pentobarbitone
(8 mg/100 g IP) and atropine (0.6 mg/100 g). When an animal was found
to be sick (body weight loss, labored breath, motionless, etc), the
dose of pentobarbitone was reduced to 3 to 4 mg/100 g. Mice were placed
in the supine position on a heating pad, and the right main carotid
artery was dissected. A microtipped transducer catheter (1.4F, Millar
Instrument Co), with the frequency response flat to 10 kHz, was
inserted into the artery and the LV. The aortic blood pressure, LV
pressure, and maximal rate of increase or decay of LV pressure,
dP/dtmax, or dP/dtmin were
recorded. HR was derived from pulse signals.
Organ Weights
Mice were killed by an overdose of pentobarbitone. Before the
heart was isolated, the chest was opened to determine whether pleural
effusion was present. The heart was immersed in saline on ice. The
LV, right ventricle (RV), and atria were separated and weighed. When an
atrial organic thrombus was present, the weight of the thrombus was
subtracted. The lungs and liver were weighed, and the tibial length was
measured. The LV was then divided at the coronary plane at its
ventricular equator. The upper halves were frozen in liquid
nitrogen for mRNA determination, and the lower halves were fixed in
10% formalin solution for histological
analysis.
Histology Analysis
Interstitial collagen content in the LV was
determined by the method described previously.17 Fixed LVs
were embedded in paraffin, and 5-µm sections were cut and stained
with 0.1% picrosirius red (Polysciences Inc). Images gathered with a
CCD video camera (Optimas, BioScan Inc) were digitized. The area
stained was calculated as a percentage of the total area within a
field. The sections were sampled in a systematic fashion, and 10 fields
in each LV were analyzed. Fields containing vessels, patches of
focal fibrosis, or artifacts were replaced by an adjacent field. Areas
of myocardium exhibiting focal fibrosis were measured and
presented as percentage of entire LV cross-sectional area.
Atrial Natriuretic Peptide mRNA
Total RNA was extracted from the LV as previously
described18 and quantified. A 755-nucleotide
EcoRI/SalI fragment of the rat atrial
natriuretic peptide (ANP) cDNA was subcloned into pGEM-3Z
for generation of cDNA probes.18 This cDNA fragment
has >90% homology with the corresponding murine sequence. A riboprobe
generated from a 177-nucleotide fragment of GAPDH cDNA was
hybridized simultaneously as control. To quantify
ANP mRNA levels, solution hybridization/nuclease protection assays were
performed with 3 µg LV RNA as previously described,18
except that nuclease protection was performed by addition of 300 µL
of digestion buffer containing RNase-T1 only (250 U, Boehringer
Mannheim) to allow for slight mismatch between rat and mouse sequences.
Nuclease-protected RNA hybrids were then detected and quantified by
phosphorimage analysis (BAS system, Fuji) after electrophoresis
on native polyacrylamide gels. The ratio of ANP/GAPDH mRNA in
each individual sample was used.
Statistics
Results have been expressed as mean±SEM or as percentages. For
parametric data, between-group comparison was made by ANOVA
followed by unpaired Student’s t test. Fisher’s exact test
was used to compare percentages between groups. The least-squares
method was used for linear correlation and regression. All statistics
were performed with the software program SigmaStat (Jandel
Scientific).
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Mortality and Incidence of Pathological Events
Five of 64 mice that were operated on were lost during surgery. All sham-operated mice (8 WT and 10 TG) survived to the time of experiment. In 13 WT and 28 TG mice with aortic stenosis, 8 mice (7 TG and 1 WT) died of HF and 1 (WT) of aortic rupture, judged by postmortem findings, during 3 to 55 days. These mice had massive pleural effusion and severe lung congestion (lung wet weight 469±41 mg, range 388 to 721 mg). Except for 1 TG mouse that died at day 3, all other mice developed severe hypertrophy (heart weight 229±19 mg, range 193 to 334; LV weight 162±15 mg, range 131 to 253 mg) and organic thrombus in the left atria.
We previously observed hypertrophy but no signs of HF in WT
mice after aortic stenosis for 6 weeks (unpublished data).
Thus, in this study, the time for functional examination was extended
to 9 weeks. At the time of the experiment, 1 WT and 14 TG mice with
aortic stenosis were so ill that they could not tolerate even a
reduced dose of pentobarbitone. These mice also had reduced body weight
postoperatively, presence of a chronic thrombus in the left atrium,
pleural effusion, and enlarged LV cavity by visual inspection (Table 1
). The incidences of
pleural effusion and atrial thrombosis were higher in the TG than WT
groups with aortic stenosis. Figure 1 shows histological
sections of the left atrium with organic thrombus and congested lungs
from a TG mouse that died at the time of experiment.
|
|
|
Functional Measurements
Before 14 TG mice were lost at the time of anesthesia,
catheterization was done in the 7 remaining TG mice.
These mice had less severe cardiac hypertrophy (heart
weight 225±15 versus 266±9 mg, P<0.05) and lung
congestion (lung wet weight 289±40 versus 388±16 mg,
P<0.01) compared with the critically ill mice.
There was no significant difference in the arterial blood
pressure between sham-operated WT and TG mice. Compared with
sham-operated mice, proximal systolic arterial
pressure increased significantly in mice with aortic stenosis,
and there was no significant difference between TG and WT groups in the
extent of systolic arterial pressure elevation
(Table 2).
|
In sham-operated mice, HR, LV dP/dtmax, and
dP/dtmin were significantly higher in the TG than
WT groups. In TG mice with aortic stenosis,
dP/dtmax, dP/dtmin, and HR
were significantly higher than in the WT counterparts (Table 2
).
However, TG and WT mice with aortic stenosis all showed a
significant fall in dP/dtmax and
dP/dtmin from respective control levels. TG mice
tended to have more pronounced reduction in
dP/dtmax than WT mice when expressed as
percentages of respective sham-operated group means (-32±5% versus
-16±6%, P=0.059). HR was similar between WT and TG groups
with or without aortic stenosis but was significantly higher in
TG than the respective WT groups (Table 2).
Body and Organ Weights
Although body weights were similar between the various groups at
the time of surgery, body weights in TG mice with aortic
stenosis were significantly lower than in other groups at the
time of experiment (Table 1). WT and TG mice had significant
increases in heart and lung weights 9 weeks after aortic
stenosis. Weights of the LV, RV, and atria were all higher than
those of sham-operated controls. TG mice with aortic stenosis
had significantly greater weights of RV, atria, and lungs (all
P<0.05). Marked cardiomegaly and LV dilatation were noticed
at autopsy in TG mice with severe hypertrophy, atrial
thrombosis, and lung congestion. TG mice with aortic stenosis
had lower liver weight than either sham-operated control or WT mice
with aortic stenosis (both P<0.05).
When results from WT and TG mice were analyzed together, lung wet weight correlated well with the whole-heart weight (r=0.807) and weights of the LV (r=0.714), RV (r=0.838), and atria (r=0.787, all P<0.001).
Interstitial Collagen Content
Collagen content in the interstitium of the LV was higher in the
TG than WT sham-operated groups (0.82±0.15% versus 0.55±0.14%, n=8
to 10, P<0.05, Figure 2a and 2b) and remained unchanged after induction of hypertrophy
in both TG and WT animals (0.80±0.15% and 0.40±0.07%,
P=NS). In the LV from mice with aortic stenosis,
however, there was apparent myocyte loss and replacement scarring
(Figure 2c), as well as expansion of adventitial fibrous tissue
(Figure 2d). The area of focal fibrosis in TG mice was
significantly larger than in the WT group (P<0.05; WT,
n=11; TG, n=17; Figure 2e).
|
ANP mRNA Expression
In WT mice, aortic stenosis increased ANP mRNA levels in
the LV by 10-fold (Figure 3). In
sham-operated TG mice, cardiac ß2-AR
overexpression alone caused a 2-fold increase in basal ANP mRNA, in
keeping with previous studies showing increased expression of
immediate-early genes by ß-adrenergic stimulation.19 20 21 22
In TG mice that underwent aortic stenosis, expression of ANP
was similarly upregulated to levels that were not significantly
different from those measured in WT mice with aortic
stenosis.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
We hypothesised that an enhanced myocardial contractility caused by ß2-AR overexpression would alleviate the onset of HF after pressure overload. Contrary to our hypothesis, we observed deleterious consequences after aortic stenosis in TG mice overexpressing ß2-AR in the heart.
Relative to WT littermates, the TG mice had higher incidences of mortality and critical illness (both due to HF), pleural effusion, and atrial thrombosis. Furthermore, they developed more severe pulmonary congestion and focal fibrosis in the LV than WT mice. By week 9 after aortic stenosis, most TG mice developed congestive HF. In the mice suffering critical illness, the presence of chronic atrial thrombus and severe lung congestion indicated LV failure, leading to stasis in the left atrium, congestion in the pulmonary vascular bed, and subsequently RV hypertrophy. Under these conditions, the LV failed to hypertrophy further, suggesting that although the maximal extent of LV hypertrophy had been reached, the pump function could not be maintained in TG mice. Thus, ß2-AR overexpression leads to functional deterioration under conditions of pressure overload, whereas it has no effect on the extent of myocardial hypertrophy per se, as indicated by the similar heart weights and ANP expression between TG and WT mice 9 weeks after pressure overload.
In TG mice with aortic stenosis, HR levels remained higher than
in WT mice. A high HR in the setting of an elevated afterload might be
deleterious by increasing the energy expenditure in the heart.
Development of severe hypertrophy would further limit the
energy supply in the TG mouse heart. We observed a larger area of focal
fibrosis in the hypertrophied LV of TG than WT mice. Previous studies
showed that chronic catecholamine stimulation results in
myocardial fibrosis,23 24 25 and this was prevented by
ß-blockade.25 Similarly, fibrous changes in the LV
myocardium have been reported in TG mice overexpressing
Gs.26 These two factors may
contribute to the adverse consequences observed in the TG mice with
pressure overload.
A similar deleterious effect of ß2-AR
overexpression has been reported previously in a murine model of
dilated cardiomyopathy and HF caused by disruption
of muscle LIM protein (MLP).27 In this case, rather than
restoring ventricular dysfunction, crossing the
MLP-deficient mice with ß2-AR overexpressing
mice significantly reduced survival.28 Thus, at least in
two HF models, ß2-AR overexpression was
deleterious. This is in keeping with the adverse outcomes from clinical
trials that observed increased cardiovascular mortality
and worsening of clinical symptoms in HF patients treated with
ß-agonists or phosphodiesterase
inhibitors.29 30 Furthermore, TG mice with
cardiac overexpression of Gs developed
cardiomyopathy and HF at old
age.26
Conversely, some studies have provided evidence that preventing ß-AR downregulation in failing hearts can be beneficial. ßARK1 is an enzyme involved in ß-AR downregulation and is closely linked to the functional state of ß-AR signaling and myocardial contractility.12 13 31 Expression of an inhibitor for ßARK1, ßARKct, in hypertrophied or MLP knockout myocardium improved cardiac function and prevented the development of HF.11 28 Thus, ßARKct expression and ß2-AR overexpression have very different effects on HF prognosis. In contrast to a marked and constant increase of HR in ß2-AR TG mice, expression of ßARKct does not increase basal HR, although overall, ventricular contractility is enhanced.13 Also, recent studies have pointed to an increased activity of Gi in mice with ß2-AR overexpression.32 Thus, there are a number of differences between the two TG models that might contribute to the different impacts on HF progression.28
In the TG line used, ß2-AR expression is
controlled by -MHC promoter.14 Before -MHC is
downregulated in hypertrophied and failing hearts,33 34 it
is likely that the transgene is downregulated after the development of
LV hypertrophy and failure. We recently found a 40%
reduction in human ß2-AR mRNA level and
receptor density in the LV of the TG mice with aortic stenosis
for 8 weeks (unpublished data, 1999). However, such a reduced level of
ß2-AR overexpression is still enough to
maintain an activated ß-adrenergic system in these TG mice,
indicated by higher levels of dP/dt and HR in the TG mice in which
cardiac function could be measured, and to result in adverse
outcomes.
In sham-operated TG mice, the interstitial collagen content of the LV was moderately higher than in WT controls. This has not been reported previously. We did not find cardiac hypertrophy in sham-operated TG mice. A preliminary study (A. Yatani, PhD, G.P. Szigeti, PhD, S. Liggett, MD, PhD, G.W. Dorn II, MD, PhD, unpublished observations, 1999) reported that hypertrophy, estimated by the patch-clamp technique (cell capacitance), may exist in ß2-AR TG mice without aortic banding. Thus, further studies are necessary to explore the phenotype of this TG model.
In conclusion, this study provides evidence that enhanced myocardial
contractility caused by 200-fold
ß2-AR overexpression does not provide
protection against pressure overload–induced HF. TG mice had a worse
prognosis after aortic stenosis, suggesting that cardiac
ß-adrenergic hyperactivity exacerbates the transition from
hypertrophy to failure by pressure overload. This finding
does not support the view that ß2-AR
overexpression could be used as gene therapy,14 at least
under the conditions of pressure overload. However, further studies are
necessary to see whether this is also true for HF of different origin
and whether ß2-AR overexpression at a low level is
beneficial.
|
Acknowledgments |
|---|
This work was supported by grants from Merck-Sharp and Dohme Research Foundation (Australia) and the Australia National Health and Medical Research Council. We are grateful to Dr R.J. Lefkowitz for providing the transgenic line, and to Elodie Percy, Sharon Harrison, Brian Jones, and the staff at Biological Research Unit for technical help.
Received March 29, 1999; revision received July 16, 1999; accepted July 20, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997;80:26L–40L.[Medline] [Order article via Infotrieve]
2. Horn EM, Bilezikian JP. Mechanisms of abnormal transmembrane signaling of the ß-adrenergic receptor in congestive heart failure. Circulation. 1990;82(suppl I):I-26–I-34.
3. Bristow MR, Minobe WA, Raynolds MV, Port JD, Rasmussen R, Ray PE, Feldman AM. Reduced ß1 receptor messenger RNA abundance in the failing human heart. J Clin Invest. 1993;92:2737–2745.
4.
Ungerer M, Parruti G, Böhm M, Puzicha M, DeBlasi
A, Erdmann E, Lohse MJ. Expression of ß-arrestines and
ß-adrenergic receptor kinases in the failing human heart. Circ
Res. 1994;74:206–213.
5.
Muntz KH, Zhao M, Miller JC. Downregulation of
myocardial ß-adrenergic receptors: receptor subtype selectivity.
Circ Res. 1994;74:369–375.
6.
Vatner DE, Sato N, Galper JB, Vatner SF.
Physiological and biochemical evidence for
coordinate increases in muscarinic receptors and
Gi during pacing-induced heart failure.
Circulation. 1996;94:102–107.
7. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with ß-adrenergic blockade. J Am Coll Cardiol. 1995;25:1154–1161.[Abstract]
8.
Heilbrunn SM, Shah P, Bristow MR, Valantine HA,
Ginsburg R, Fowler MB. Increased ß-receptor density and improved
hemodynamic response to catecholamine
stimulation during long-term metoprolol therapy in heart failure from
dilated cardiomyopathy. Circulation. 1989;79:483–490.
9.
Liang CS, Frantz RP, Suematsu M, Sakamoto S,
Sullebarger JT, Fan TM, Guthinger L. Chronic ß-adrenoceptor
blockade prevents the development of ß-adrenergic subsensitivity in
experimental right-sided congestive heart failure in dogs.
Circulation. 1991;84:254–266.
10. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. Circ Res. 1996;94:2285–2296.
11.
Akhter SA, Skaer CA, Kypson AP, McDonald PH, Peppel KC,
Glower DD, Lefkowitz RJ, Koch WJ. Restoration of ß-adrenergic
signaling in failing cardiac ventricular myocytes via
adenoviral-mediated gene transfer. Proc Natl Acad Sci
U S A. 1997;94:12100–12105.
12.
Iaccarino G, Tomhave ED, Lefkowitz RJ, Koch WJ.
Reciprocal in vivo regulation of myocardial G protein-coupled receptor
kinase expression by ß-adrenergic receptor stimulation and
blockade. Circulation. 1998;98:1783–1789.
13.
Koch WJ, Rockman HA, Samama P, Hamilton R, Bond RA,
Milano CA, Lefkowitz RJ. Cardiac function in mice overexpressing
the ß-adrenergic receptor kinase or a ßARK
inhibitor. Science. 1995;268:1350–1353.
14.
Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR,
Chien KR, Johnson TD, Bond RA, Lefkowitz RJ. Enhanced myocardial
function in transgenic mice overexpressing the
ß2-adrenergic receptor. Science. 1994;264:582–586.
15. Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, Apparsundaram S, Hyek MF, Kenakin TP, Allen LF, Lefkowitz RJ. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the ß2-adrenoceptor. Nature. 1995;374:272–276.[Medline] [Order article via Infotrieve]
16.
Rockman HA, Ross RS, Harris AN, Knowlton KU,
Steinhelper ME, Field LJ, Ross J Jr, Chien KR. Segregation of
atrial-specific and inducible expression of an atrial
natriuretic factor transgene in an in vivo murine model of
cardiac hypertrophy. Proc Natl Acad Sci U S A. 1991;88:8277–8281.
17. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest. 1994;93:2578–2583.
18.
Autelitano DJ, Woodcock EA. Selective activation
of 1A-adrenergic receptors in neonatal
cardiac myocytes is sufficient to cause hypertrophy and
differential regulation of 1-adrenergic
receptor subtype mRNAs. J Mol Cell Cardiol. 1998;30:1515–1523.[Medline]
[Order article via Infotrieve]
19.
Iwaki K, Sukhatme VP, Shubeita HE, Chien KR. -
and ß-adrenergic stimulation induces distinct patterns of immediate
early gene expression in neonatal rat myocardial cells. J
Biol Chem. 1990;265:13809–13817.
20. Bogoyevitch MA, Andersson MB, Gillespie-Brown J, Clerk A, Glennon PE, Fuller SJ, Sugden PH. Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. Biochem J. 1996;314:115–121.
21.
Bishopric NH, Sato B, Webster KA. ß-Adrenergic
regulation of a myocardial actin gene via a cyclic AMP-independent
pathway. J Biol Chem. 1992;267:20932–20936.
22. Iaccarino G, Dolber PC, Lefkowitz RJ, Koch WJ. ß-Adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy. Circ Res. 1999;33:396–401.
23. Masson S, Arosio B, Luvara G, Gagliano N, Fiordaliso F, Santambrogio D, Vergani C, Latini R, Annoni G. Remodeling of cardiac extracellular matrix during ß-adrenergic stimulation: upregulation of SPARC in the myocardium of adult rats. J Mol Cell Cardiol. 1998;30:1505–1514.[Medline] [Order article via Infotrieve]
24.
Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark
WA. Isoproterenol-induced myocardial fibrosis in relation to myocyte
necrosis. Circ Res. 1989;65:657–670.
25.
Rosenbaum JS, Ginsburg R, Billingham ME, Hoffman BB.
Effects of adrenergic receptor antagonists on cardiac
morphological and functional alterations in rats harboring
pheochromocytoma. J Pharmacol Exp Ther. 1987;241:354–360.
26.
Iwase M, Bishop SP, Uechi M, Vatner DE, Shannon RP,
Kudej RK, Wight DC, Wagner TE, Ishikawa Y, Homcy CJ, Vatner SF. Adverse
effects of chronic endogenous sympathetic drive induced by
cardiac Gs overexpression. Circ
Res. 1996;78:517–524.
27. Arber S, Hunter JJ, Ross J Jr, Hongo M, Sansig G, Borg J, Perriard JC, Chien KR, Caroni P. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy and heart failure. Cell. 1997;88:393–403.[Medline] [Order article via Infotrieve]
28.
Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ,
Ross J Jr, Lefkowitz RJ, Koch WJ. Expression of a ß-adrenergic
receptor kinase 1 inhibitor prevents the development of
myocardial failure in gene-targeted mice. Proc Natl Acad Sci
U S A. 1998;95:7000–7005.
29.
Roubin GS, Choong CYP, Devenish-Meares S, Sadick NN,
Fletcher PJ, Kelly DT, Harris PJ. ß-Adrenergic stimulation of
the failing ventricle: a double-blind, randomized trial of sustained
oral therapy with prenalterol. Circulation. 1984;69:955–962.
30. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL, the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325:1468–1475.[Abstract]
31.
Rockman HA, Choi D, Akhter SA, Jaber M, Giros B,
Lefkowitz RJ, Caron MG, Koch WJ. Control of myocardial contractile
function by the level of ß-adrenergic receptor kinase 1 in
gene-targeted mice. J Biol Chem. 1998;273:18180–18184.
32.
Xiao RP, Avdonin P, Zhou YY, Cheng H, Akhter SA,
Eschenhagen T, Lefkowitz RJ, Koch WJ, Lakatta EG. Coupling of
ß2-adrenoceptor to Gi
proteins and its physiological relevance in murine
cardiac myocytes. Circ Res. 1999;84:43–52.
33. Izumo S, Lompre AM, Matsuoka R, Koren G, Schwartz K, Nadal-Ginard B, Mahdavi V. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. J Clin Invest. 1987;79:970–977.
34.
Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ,
Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB,
Groves BM, Gilbert EM, Bristow MR. Changes in gene expression in the
intact human heart: downregulation of -myosin heavy chain in
hypertrophied, failing ventricular myocardium.
J Clin Invest. 1997;100:2315–2324.[Medline]
[Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  L. Pretorius, X.-J. Du, E. A. Woodcock, H. Kiriazis, R. C.Y. Lin, S. Marasco, R. L. Medcalf, Z. Ming, G. A. Head, J. W. Tan, et al. Reduced Phosphoinositide 3-Kinase (p110{alpha}) Activation Increases the Susceptibility to Atrial Fibrillation Am. J. Pathol., September 1, 2009; 175(3): 998 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Grote-Wessels, H. A. Baba, P. Boknik, A. El-Armouche, L. Fabritz, H.-J. Gillmann, D. Kucerova, M. Matus, F. U. Muller, J. Neumann, et al. Inhibition of protein phosphatase 1 by inhibitor-2 exacerbates progression of cardiac failure in a model with pressure overload Cardiovasc Res, August 1, 2008; 79(3): 464 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Vinge, P. W. Raake, and W. J. Koch Gene Therapy in Heart Failure Circ. Res., June 20, 2008; 102(12): 1458 - 1470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Xu, E. D. Lekgabe, X.-M. Gao, Z. Ming, G. W. Tregear, A. M. Dart, R. A. D. Bathgate, C. S. Samuel, and X.-J. Du Endogenous Relaxin Does Not Affect Chronic Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis Endocrinology, February 1, 2008; 149(2): 476 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-J. Du, X.-M. Gao, H. Kiriazis, X.-L. Moore, Z. Ming, Y. Su, A. M. Finch, R. A. Hannan, A. M. Dart, and R. M. Graham Transgenic {alpha}1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival Cardiovasc Res, September 1, 2006; 71(4): 735 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kiriazis, X.-J. Du, X. Feng, E. Hotchkin, T. Marshall, S. Finch, X.-M. Gao, G. Lambert, J. K. Choate, and D. M. Kaye Preserved left ventricular structure and function in mice with cardiac sympathetic hyperinnervation Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1359 - H1365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Brucato, Y Shinar, G Brambilla, L Robbiolo, G Ferrioli, M C Patrosso, D Zanni, S Penco, E Boiani, A Ghirardello, et al. Idiopathic recurrent acute pericarditis: familial Mediterranean fever mutations and disease evolution in a large cohort of Caucasian patients Lupus, September 1, 2005; 14(9): 670 - 674. [Abstract] [PDF]
|
|
|
|
 |
|
 E. D. Lekgabe, H. Kiriazis, C. Zhao, Q. Xu, X. L. Moore, Y. Su, R. A.D. Bathgate, X.-J. Du, and C. S. Samuel Relaxin Reverses Cardiac and Renal Fibrosis in Spontaneously Hypertensive Rats Hypertension, August 1, 2005; 46(2): 412 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-M. Gao, H. Kiriazis, X.-L. Moore, X.-H. Feng, K. Sheppard, A. Dart, and X.-J. Du Regression of pressure overload-induced left ventricular hypertrophy in mice Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2702 - H2707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-C. Fan, G. Chu, B. Mitton, Q. Song, Q. Yuan, and E. G. Kranias Small Heat-Shock Protein Hsp20 Phosphorylation Inhibits {beta}-Agonist-Induced Cardiac Apoptosis Circ. Res., June 11, 2004; 94(11): 1474 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Wang, H. R. Brunner, and M. Burnier Determination of cardiac contractility in awake unsedated mice with a fluid-filled catheter Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H806 - H814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Dorn II and J. D. Molkentin Manipulating Cardiac Contractility in Heart Failure: Data From Mice and Men Circulation, January 20, 2004; 109(2): 150 - 158. [Full Text] [PDF]
|
|
|
|
 |
|
 J.R. Keys and W.J. Koch The Adrenergic Pathway and Heart Failure Recent Prog. Horm. Res., January 1, 2004; 59(1): 13 - 30. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Lohse, S. Engelhardt, and T. Eschenhagen What Is the Role of {beta}-Adrenergic Signaling in Heart Failure? Circ. Res., November 14, 2003; 93(10): 896 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Okumura, G. Takagi, J.-i. Kawabe, G. Yang, M.-C. Lee, C. Hong, J. Liu, D. E. Vatner, J. Sadoshima, S. F. Vatner, et al. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload PNAS, August 19, 2003; 100(17): 9986 - 9990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schwarz, E. Percy, X.-M. Gao, A. M. Dart, G. Richardt, and X.-J. Du Altered calcium transient and development of hypertrophy in {beta}2-adrenoceptor overexpressing mice with and without pressure overload Eur J Heart Fail, March 1, 2003; 5(2): 131 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-J. Du, C. S Samuel, X.-M. Gao, L. Zhao, L. J Parry, and G. W Tregear Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice: a gender-specific phenotype Cardiovasc Res, February 1, 2003; 57(2): 395 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. del Monte and R. J Hajjar Targeting calcium cycling proteins in heart failure through gene transfer J. Physiol., January 1, 2003; 546(1): 49 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-J. Du, T. J. Cole, N. Tenis, X.-M. Gao, F. Kontgen, B. E. Kemp, and J. Heierhorst Impaired Cardiac Contractility Response to Hemodynamic Stress in S100A1-Deficient Mice Mol. Cell. Biol., April 15, 2002; 22(8): 2821 - 2829. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Wu, J. Hagaman, S. Kim, R. L. Reddick, and N. Maeda Aortic Constriction Exacerbates Atherosclerosis and Induces Cardiac Dysfunction in Mice Lacking Apolipoprotein E Arterioscler Thromb Vasc Biol, March 1, 2002; 22(3): 469 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kiriazis, Y. Sato, V. J Kadambi, A. G Schmidt, M. J Gerst, B. D Hoit, and E. G Kranias Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis Cardiovasc Res, February 1, 2002; 53(2): 372 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zaugg, M. C. Schaub, T. Pasch, and D. R. Spahn Modulation of {beta}-adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action Br. J. Anaesth., January 1, 2002; 88(1): 101 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-J. Du Sympathoadrenergic mechanisms in functional regulation and development of cardiac hypertrophy and failure: findings from genetically engineered mice Cardiovasc Res, June 1, 2001; 50(3): 443 - 453. [Full Text] [PDF]
|
|
|
|
|
|
K.-D. Schluter, X.-J. Du, D. J. Autelitano, R. Dilley, B.-H. Wang, A. M. Dart, and E. A. Woodcock {beta}2-Adrenergic Receptor Overexpression Exacerbates Development of Heart Failure After Aortic Stenosis Response Circulation, January 16, 2001; 103 (2): e11 - e11. [Full Text] [PDF]
|
|
|
|
|
|
X.-J. Du, X.-M. Gao, B. Wang, G. L Jennings, E. A Woodcock, and A. M Dart Age-dependent cardiomyopathy and heart failure phenotype in mice overexpressing {beta}2-adrenergic receptors in the heart Cardiovasc Res, December 1, 2000; 48(3): 448 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-J. Du, X.-M. Gao, G. L. Jennings, A. M. Dart, and E. A. Woodcock Preserved ventricular contractility in infarcted mouse heart overexpressing beta 2-adrenergic receptors Am J Physiol Heart Circ Physiol, November 1, 2000; 279(5): H2456 - H2463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Sheridan, D. J. Autelitano, B. Wang, E. Percy, E. A. Woodcock, and X.-J. Du {beta}2-Adrenergic receptor overexpression driven by {alpha}-MHC promoter is downregulated in hypertrophied and failing myocardium Cardiovasc Res, July 1, 2000; 47(1): 133 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Hajjar, F. del Monte, T. Matsui, and A. Rosenzweig Prospects for Gene Therapy for Heart Failure Circ. Res., March 31, 2000; 86(6): 616 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-L. Laugwitz, H.-J. Weig, A. Moretti, E. Hoffmann, P. Ueblacker, I. Pragst, K. Rosport, A. Schomig, and M. Ungerer Gene Transfer of Heterologous G Protein-Coupled Receptors to Cardiomyocytes : Differential Effects on Contractility Circ. Res., April 13, 2001; 88(7): 688 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ito, X. Yan, X. Feng, W. J. Manning, W. H. Dillmann, and B. H. Lorell Transgenic Expression of Sarcoplasmic Reticulum Ca2+ ATPase Modifies the Transition From Hypertrophy to Early Heart Failure Circ. Res., August 31, 2001; 89(5): 422 - 429. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||